Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.
Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia.
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
尽管现在有几项临床试验正在测试可能的治疗方法，但全球对 COVID-19 爆发的反应主要局限于监测/遏制。我们在这里报告，伊维菌素，一种已被 FDA 批准的抗寄生虫药物，先前已被证明在体外具有广谱抗病毒活性，是致病病毒（SARS-CoV-2）的抑制剂，在感染 SARS-CoV-2 后 2 小时向 Vero-hSLAM 细胞中单次添加伊维菌素能够在 48 小时内使病毒 RNA 减少约 5000 倍。因此，伊维菌素值得进一步研究，以评估其对人类可能的益处。
Zotero 插件